Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir

Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-19 (refs. (1,2)). However, because SARS-CoV-2 has evolved to become resistant to other therapeutic modalities(3–9), there is a concern that the same could occur for n...

Descripción completa

Detalles Bibliográficos
Autores principales: Iketani, Sho, Mohri, Hiroshi, Culbertson, Bruce, Hong, Seo Jung, Duan, Yinkai, Luck, Maria I., Annavajhala, Medini K., Guo, Yicheng, Sheng, Zizhang, Uhlemann, Anne-Catrin, Goff, Stephen P., Sabo, Yosef, Yang, Haitao, Chavez, Alejandro, Ho, David D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849135/
https://www.ncbi.nlm.nih.gov/pubmed/36351451
http://dx.doi.org/10.1038/s41586-022-05514-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849135/
https://www.ncbi.nlm.nih.gov/pubmed/36351451
http://dx.doi.org/10.1038/s41586-022-05514-2

Ejemplares similares